Epidermolysis Bullosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major epidermolysis bullosa markets reached a value of US$ 2,596.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3,929.8 Million by 2034, exhibiting a growth rate (CAGR) of 3.84% during 2024-2034.
The epidermolysis bullosa market has been comprehensively analyzed in IMARC's new report titled " Epidermolysis Bullosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Epidermolysis bullosa (EB) refers to a rare genetic disorder that mainly affects the skin and mucous membrane. It is primarily caused by mutations in genes that produce proteins responsible for holding the layers of skin together. As a result, people suffering from the ailment have extremely fragile skin that blisters and tears up easily, even with minor trauma or friction. Depending on the affected layers of the skin and the severity, this condition is classified into EB simplex, junctional EB, dystrophic EB, and Kindler syndrome. Other common symptoms of the disease include thick or unformed nails, blisters inside the mouth and throat, hair loss, thin skin, tiny pimple-like bumps, dental problems, difficulty swallowing, itchy and painful skin, fused fingers, or toes, etc. The diagnosis of this disorder typically requires an evaluation of the patient’s underlying indications and medical history. A skin biopsy and review of the tissue sample using advanced microscopic techniques are also recommended to help healthcare providers identify the layers of the skin affected and determine the type of EB.
The increasing prevalence of inherited diseases, which cause mutations in the genome and affect the strength and structure of connective tissues within the body, is primarily driving the epidermolysis bullosa market. In addition to this, the inflating demand for molecular genetic testing that can aid in early diagnosis of the disorder with more personalized patient care to minimize complexities is also bolstering the market growth. Furthermore, the widespread utilization of effective drugs, such as amitriptyline, gabapentin, morphine, etc., to treat severe types of EB and provide long-term pain relief is acting as another significant growth-inducing factor. Apart from this, the escalating application of genetically modified skin graft techniques, which enhance wound healing, restore skin functioning, and improve the appearance of damaged skin, is further creating a positive outlook for the market. Moreover, the rising popularity of protein replacement therapies for treating the condition, since they can replace the missing or defective protein to potentially reverse the structural and molecular defects in the skin, is expected to drive the epidermolysis bullosa market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the epidermolysis bullosa market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for epidermolysis bullosa and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the epidermolysis bullosa market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the epidermolysis bullosa market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the epidermolysis bullosa market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current epidermolysis bullosa marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the epidermolysis bullosa market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the epidermolysis bullosa market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the epidermolysis bullosa market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of epidermolysis bullosa across the seven major markets?
What is the number of prevalent cases (2018-2034) of epidermolysis bullosa by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of epidermolysis bullosa by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of epidermolysis bullosa by type across the seven major markets?
How many patients are diagnosed (2018-2034) with epidermolysis bullosa across the seven major markets?
What is the size of the epidermolysis bullosa patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of epidermolysis bullosa?
What will be the growth rate of patients across the seven major markets?
Epidermolysis Bullosa: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for epidermolysis bullosa drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the epidermolysis bullosa market?
What are the key regulatory events related to the epidermolysis bullosa market?
What is the structure of clinical trial landscape by status related to the epidermolysis bullosa market?
What is the structure of clinical trial landscape by phase related to the epidermolysis bullosa market?
What is the structure of clinical trial landscape by route of administration related to the epidermolysis bullosa market?
The epidermolysis bullosa market has been comprehensively analyzed in IMARC's new report titled " Epidermolysis Bullosa Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Epidermolysis bullosa (EB) refers to a rare genetic disorder that mainly affects the skin and mucous membrane. It is primarily caused by mutations in genes that produce proteins responsible for holding the layers of skin together. As a result, people suffering from the ailment have extremely fragile skin that blisters and tears up easily, even with minor trauma or friction. Depending on the affected layers of the skin and the severity, this condition is classified into EB simplex, junctional EB, dystrophic EB, and Kindler syndrome. Other common symptoms of the disease include thick or unformed nails, blisters inside the mouth and throat, hair loss, thin skin, tiny pimple-like bumps, dental problems, difficulty swallowing, itchy and painful skin, fused fingers, or toes, etc. The diagnosis of this disorder typically requires an evaluation of the patient’s underlying indications and medical history. A skin biopsy and review of the tissue sample using advanced microscopic techniques are also recommended to help healthcare providers identify the layers of the skin affected and determine the type of EB.
The increasing prevalence of inherited diseases, which cause mutations in the genome and affect the strength and structure of connective tissues within the body, is primarily driving the epidermolysis bullosa market. In addition to this, the inflating demand for molecular genetic testing that can aid in early diagnosis of the disorder with more personalized patient care to minimize complexities is also bolstering the market growth. Furthermore, the widespread utilization of effective drugs, such as amitriptyline, gabapentin, morphine, etc., to treat severe types of EB and provide long-term pain relief is acting as another significant growth-inducing factor. Apart from this, the escalating application of genetically modified skin graft techniques, which enhance wound healing, restore skin functioning, and improve the appearance of damaged skin, is further creating a positive outlook for the market. Moreover, the rising popularity of protein replacement therapies for treating the condition, since they can replace the missing or defective protein to potentially reverse the structural and molecular defects in the skin, is expected to drive the epidermolysis bullosa market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the epidermolysis bullosa market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for epidermolysis bullosa and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the epidermolysis bullosa market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the epidermolysis bullosa market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the epidermolysis bullosa market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current epidermolysis bullosa marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the epidermolysis bullosa market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the epidermolysis bullosa market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the epidermolysis bullosa market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of epidermolysis bullosa across the seven major markets?
What is the number of prevalent cases (2018-2034) of epidermolysis bullosa by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of epidermolysis bullosa by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of epidermolysis bullosa by type across the seven major markets?
How many patients are diagnosed (2018-2034) with epidermolysis bullosa across the seven major markets?
What is the size of the epidermolysis bullosa patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of epidermolysis bullosa?
What will be the growth rate of patients across the seven major markets?
Epidermolysis Bullosa: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for epidermolysis bullosa drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the epidermolysis bullosa market?
What are the key regulatory events related to the epidermolysis bullosa market?
What is the structure of clinical trial landscape by status related to the epidermolysis bullosa market?
What is the structure of clinical trial landscape by phase related to the epidermolysis bullosa market?
What is the structure of clinical trial landscape by route of administration related to the epidermolysis bullosa market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 EPIDERMOLYSIS BULLOSA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 EPIDERMOLYSIS BULLOSA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 EPIDERMOLYSIS BULLOSA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 EPIDERMOLYSIS BULLOSA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 EPIDERMOLYSIS BULLOSA - UNMET NEEDS
10 EPIDERMOLYSIS BULLOSA - KEY ENDPOINTS OF TREATMENT
11 EPIDERMOLYSIS BULLOSA - MARKETED PRODUCTS
11.1 List of Epidermolysis Bullosa Marketed Drugs Across the Top 7 Markets
11.1.1 Filsuvez (Birch triterpenes) - Amryt Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 EPIDERMOLYSIS BULLOSA - PIPELINE DRUGS
12.1 List of Epidermolysis Bullosa Pipeline Drugs Across the Top 7 Markets
12.1.1 allo-APZ2-EB - Rheacell
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Beremagene Geperpavec - Krystal Biotech
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 FCX-007 - Castle Creek Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 EB101 - Abeona Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 PTR 01 - Phoenix Tissue Repair Inc
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. EPIDERMOLYSIS BULLOSA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. EPIDERMOLYSIS BULLOSA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 EPIDERMOLYSIS BULLOSA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Epidermolysis Bullosa - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Epidermolysis Bullosa - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Epidermolysis Bullosa - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Epidermolysis Bullosa - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Epidermolysis Bullosa - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Epidermolysis Bullosa - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Epidermolysis Bullosa - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Epidermolysis Bullosa - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Epidermolysis Bullosa - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Epidermolysis Bullosa - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Epidermolysis Bullosa - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Epidermolysis Bullosa - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Epidermolysis Bullosa - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Epidermolysis Bullosa - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Epidermolysis Bullosa - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Epidermolysis Bullosa - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Epidermolysis Bullosa - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Epidermolysis Bullosa - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Epidermolysis Bullosa - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Epidermolysis Bullosa - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Epidermolysis Bullosa - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Epidermolysis Bullosa - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Epidermolysis Bullosa - Access and Reimbursement Overview
16 EPIDERMOLYSIS BULLOSA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 EPIDERMOLYSIS BULLOSA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 EPIDERMOLYSIS BULLOSA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 EPIDERMOLYSIS BULLOSA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 EPIDERMOLYSIS BULLOSA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 EPIDERMOLYSIS BULLOSA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 EPIDERMOLYSIS BULLOSA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 EPIDERMOLYSIS BULLOSA - UNMET NEEDS
10 EPIDERMOLYSIS BULLOSA - KEY ENDPOINTS OF TREATMENT
11 EPIDERMOLYSIS BULLOSA - MARKETED PRODUCTS
11.1 List of Epidermolysis Bullosa Marketed Drugs Across the Top 7 Markets
11.1.1 Filsuvez (Birch triterpenes) - Amryt Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 EPIDERMOLYSIS BULLOSA - PIPELINE DRUGS
12.1 List of Epidermolysis Bullosa Pipeline Drugs Across the Top 7 Markets
12.1.1 allo-APZ2-EB - Rheacell
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Beremagene Geperpavec - Krystal Biotech
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 FCX-007 - Castle Creek Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 EB101 - Abeona Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 PTR 01 - Phoenix Tissue Repair Inc
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. EPIDERMOLYSIS BULLOSA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. EPIDERMOLYSIS BULLOSA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 EPIDERMOLYSIS BULLOSA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Epidermolysis Bullosa - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Epidermolysis Bullosa - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Epidermolysis Bullosa - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Epidermolysis Bullosa - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Epidermolysis Bullosa - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Epidermolysis Bullosa - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Epidermolysis Bullosa - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Epidermolysis Bullosa - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Epidermolysis Bullosa - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Epidermolysis Bullosa - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Epidermolysis Bullosa - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Epidermolysis Bullosa - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Epidermolysis Bullosa - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Epidermolysis Bullosa - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Epidermolysis Bullosa - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Epidermolysis Bullosa - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Epidermolysis Bullosa - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Epidermolysis Bullosa - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Epidermolysis Bullosa - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Epidermolysis Bullosa - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Epidermolysis Bullosa - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Epidermolysis Bullosa - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Epidermolysis Bullosa - Access and Reimbursement Overview
16 EPIDERMOLYSIS BULLOSA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 EPIDERMOLYSIS BULLOSA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 EPIDERMOLYSIS BULLOSA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
